Health Innovators – Pierre Luzeau

Getting a drug from idea to market is a complex process that requires a number of stakeholders, from research to development to manufacturing. While larger companies can go it alone for more of these functions, smaller biotechs must partner with CROs and CDMOs along the way.

French life sciences company SEQENS provides both those services for these companies, as well as manufacturing its own generics. Last week the company, which has a plant in Devens, Massachusestts, hosted an event in Boston’s Kendall Square to talk to local biotechs about what they do.

At the event, pharmaphorum editor-in-chief Jonah Comstock had a chance to sit down with SEQENS CEO Pierre Luzeau and talk about how his company juggles so many roles, what advantages that versatility has for the biotechs they work with, and some recent developments for the company around cell and gene therapy. They also discuss the importance of sustainability for everyone in the pharma ecosystem.

Check out the full interview below.